BSc Biol, PhD Molecular Oncology
monica.martinez@iisgaliciasur.es
Tel: 986 217 463
Our research unit is formed by a multidisciplinary team composed of biologists, medical oncologists and pathologists with the common objective of understanding the molecular alterations involved in cancer to help in patients´ diagnosis and prognosis.
We have currently several projects on going aimed to find new biomarkers and molecular targets that can be used towards a precision medicine, opening new avenues in the therapeutic options, using tissue and liquid biopsies. We believe that our work is predestined to have a clear clinical application that could change cancer diagnosis and would help oncologists for personalized treatments.
PREDOC STUDENTS
• Jenifer Brea, del IISGS
(co-dirigida con Jose Tubío)
• Pablo Fonseca, del IISGS
(co-dirigida con David Posada)
• Ana Oitabén Fernández, del CiMUS – USC
(co dirigida con Jose Tubío)
• Laura Juaneda-Magdalena, de Anatomía Patológica e IISGS (co-dirigida con González Carreró)
• Aida López López, de Farmacia del IISGS
LAB ASSISTANT
• Irene Alonso Álvarez, IISGS
IISGS Cols.
Oncología Médica CHUVI:
• Dr. Joaquín Casal (Jefe de Servicio)
• Dr. Martín Lázaro
• Dra. Isaura Fernández
• Dra. Carme García Benito
• Dra. M Elena Gallardo Martín
Anatomía Patológica CHUVI:
• Dr. Joaquín González Carrero Fojón (Jefe servicio)
• Dr. Jose A. Ortiz Rey
• Dra. M. Pilar San Miguel
• Dra. Laura Juaneda-Magdalena
Universidade de Vigo:
• Dr. David Posada
• Dr. Joao Alves
EXTERNAL Cols
CHUS – Oncología Médica
• Dr. Luis León
• Dr Urbano Anido
CHUS – Anatomía Patológica
• Dr. Máximo Fraga
• Dr. Ihab Abdulkader
Hospital 12 de Octubre
• Dr. Jesús Paramio
• Dr. Cristian Suarez
CiMUS
• Dr. Jose Tubio
ONCOMET
• Dra. Laura Muinelo
• Dra. Clotilde Costa
• Segovia*, San José-Enériz* , Munera-Maravilla*, Martínez-Fernández M et al. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nature Medicine, 25: 1073–1081 (2019)
• Rubio C*; Martinez-Fernandez M*; et al. Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status. Clinical Cancer Research. 25, pp. 390 – 402 (2019)
• Dueñas, Perez-Figueroa…,Mónica Martínez-Fernández. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Scientific Reports, 9: 10362 (2019)
• Segovia C, Paramio JM, Martinez-Fernandez M. Epigenetic mutations and cancer therapy Effectiven(EZH2). Translational Cancer Research. 6, pp. Supl 3 (2017)
• Segovia C*, Martínez-Fernández M* et al. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget, 8:10531-10542 (2017)
• Martínez Fernández M et al. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget. 6 – 39, pp. 42258 – 42333 (2015)
• Martínez Fernández M et al. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clinical Epigenetics. 7, pp. 109 (2015)
• Santos M*; Martínez Fernández M* et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Research. 74 – 22, pp. 6565 – 6642 (2014)
• Proyecto de Investigación en Salud del ISCIII, AES2021, “UNA PERSPECTIVA EPIGENÉTICA EN LA ERA DE LA INMUNOONCOLOGIA”, (2022-2024)
• Proyecto Miguel Servet ISCIII: “Searching for potential predictive biomarkers for immunotherapy”, (2020-2024)
• Ideas Semilla AECC: “Estudio de nuevos mecanismos moleculares en la respuesta a inmmunoterapia”, (2020-2022)
• OCTOPUS project: Oncoloxía Customizada para Tratar Os PUlmónS (https://proxectooctopus.org/) funded by the Vigo Against Cancer Association, (2020-)
• Proyecto de Investigación en Salud del ISCIII, AES2019, “Ampliando el horizonte para los biomarcadores predictores de respuesta a inmmunoterapia”, (2020)
• AECC Investigator “Estudio del impacto funcional de la transducción de secuencias reguladoras mediada por retrotransposones altamente mutagénicos” (2018-2020).